4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AC Immune SA (ACIU) operates in the Biotechnology industry and is headquartered in Lausanne, Switzerland with about 90 employees. Its market capitalization is roughly $227 million. In the fiscal year ended 2025-12-31, ACIU reported $4M in revenue and ($70M) in net income.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Interactive charts & full statements → Open the ACIU valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $4M | $27M | $15M | $4M |
| Operating Income (EBIT) | ($69M) | ($52M) | ($54M) | ($71M) |
| Net Income | ($70M) | ($51M) | ($54M) | ($71M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $1M | $1M | $1M | — |
| Operating Income (EBIT) | ($15M) | ($14M) | ($16M) | ($19M) | ($19M) | — |
| Net Income | ($15M) | ($14M) | ($16M) | ($21M) | ($19M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $154M | $231M | $183M | $186M | — |
| Total Liabilities | $109M | $119M | $22M | $17M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACIU viewer.
About TickerBase · Data methodology & sources